Treatment outcome of pediatric hodgkin's lymphoma at the national cancer institute (NCI) / Hani Hemmat Abdelmonem Abdelhamid ; Supervised Iman A. Sidhom , Iman A. Attia , Amr M. Amin
Material type: TextLanguage: English Publication details: Cairo : Hani Hemmat Abdelmonem Abdelhamid , 2015Description: 195 P. : facsimiles ; 25cmOther title:- نتائج علاج سرطان الغدد الليمفاوية (هودجكن) لدى الأطفال في المعهد القومي للاورام - جامعة القاهرة [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.05.M.Sc.2015.Ha.T (Browse shelf(Opens below)) | Not for loan | 01010110067887000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.05.M.Sc.2015.Ha.T (Browse shelf(Opens below)) | 67887.CD | Not for loan | 01020110067887000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
Hodgkin lymphoma (HL) accounts for 8% to 10% of all childhood cancer. It displays characteristic epidemiological, clinical, and pathological features according to various geographic areas. We aimed to assess the epidemiological aspects, clinicopathological features, and treatment outcome of pediatric HL treated at Pediatric Oncology Department, National Cancer Institute, Cairo University. We carried a retrospective study by reviewing medical records for all patients admitted with the diagnosis of HL over 5 years during the period between January 2008 till end of December 2012, and they were followed up till the end of December 2013. Age of the patients at presentation ranged from 3 to 18 years (median 11 years) and male: female ratio 1.6:1. Cervical lymphadenopathy was the most common presentation (94.8%). Mixed cellularity subtype was dominant (44.7%), followed by nodular sclerosis (34.3%), lymphocyte-rich (10.4%) with lymphocyte depletion being the least dominant (3.7%). About half of patients (45.5 %) had advanced disease (Ann Arbor stage III/IV disease). The duration of follow-up ranged from 6 to 56.5 months (median 35.8 months). The 5-year overall survival and event-free survival for patients were 94% and 79% respectively
Issued also as CD
There are no comments on this title.